Adaptive Biotechnologies posted a 36% year-over-year revenue increase to $58.9 million for the second quarter driven primarily by its minimal residual disease (MRD) testing business. Revenues from the ClonoSeq MRD clinical tests rose 57%, reflecting increased adoption and expanded reimbursement. The company reported narrower net losses compared to the prior year, alongside steady growth in its immune medicine segment. Ongoing growth is anchored by improved pricing, increased test volumes, and regulatory milestones in MRD pharma business.